REGENERON PHARMACEUTICALS, INC. Contracts Revenue (Deprecated 2018-01-31)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Contracts Revenue (Deprecated 2018-01-31) of $2.90 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-15.
Discontinued › Income Statement › Other Income
us-gaap:ContractsRevenue · last filed 2013-02-15
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2012-12-31 was $669.00K, a 27.83% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2012-09-30 was $879.00K, a 44.23% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2012-06-30 was $875.00K, a 55.67% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for the quarter ending 2012-03-31 was $477.00K, a 77.52% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2012 was $2.90M, a 56.05% decline from fiscal 2011.
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2011 was $6.60M, a 4.98% decline from fiscal 2010.
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2010 was $6.95M, a 7.94% increase from fiscal 2009.
- REGENERON PHARMACEUTICALS, INC. contracts revenue (deprecated 2018-01-31) for fiscal 2009 was $6.43M, a 9.00% decline from fiscal 2008.
| Period end | Contracts Revenue (Deprecated 2018-01-31) 3 month | Contracts Revenue (Deprecated 2018-01-31) 6 month | Contracts Revenue (Deprecated 2018-01-31) 9 month | Contracts Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2012-12-31 | $669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $1.55M derived: sum of 2 quarters · filed 2013-02-15 | $2.42M derived: sum of 3 quarters · filed 2013-02-15 | $2.90M 10-K · filed 2013-02-15 |
| 2012-09-30 | $879.00K 10-Q · filed 2012-10-24 | $1.75M derived: sum of 2 quarters · filed 2012-10-24 | $2.23M 10-Q · filed 2012-10-24 | $3.16M derived: sum of 4 quarters · filed 2013-02-15 |
| 2012-06-30 | $875.00K 10-Q · filed 2012-07-25 | $1.35M 10-Q · filed 2012-07-25 | $2.28M derived: sum of 3 quarters · filed 2013-02-15 | $3.85M derived: sum of 4 quarters · filed 2013-02-15 |
| 2012-03-31 | $477.00K 10-Q · filed 2012-04-26 | $1.40M derived: sum of 2 quarters · filed 2013-02-15 | $2.98M derived: sum of 3 quarters · filed 2013-02-15 | $4.95M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-12-31 | $927.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $2.50M derived: sum of 2 quarters · filed 2013-02-15 | $4.48M derived: sum of 3 quarters · filed 2013-02-15 | $6.60M 10-K · filed 2013-02-15 |
| 2011-09-30 | $1.58M 10-Q · filed 2012-10-24 | $3.55M derived: sum of 2 quarters · filed 2012-10-24 | $5.67M 10-Q · filed 2012-10-24 | $6.99M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $1.97M 10-Q · filed 2012-07-25 | $4.10M 10-Q · filed 2012-07-25 | $5.42M derived: sum of 3 quarters · filed 2013-02-15 | $7.08M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $2.12M 10-Q · filed 2012-04-26 | $3.44M derived: sum of 2 quarters · filed 2013-02-15 | $5.11M derived: sum of 3 quarters · filed 2013-02-15 | $7.18M derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $2.98M derived: sum of 2 quarters · filed 2013-02-15 | $5.06M derived: sum of 3 quarters · filed 2013-02-15 | $6.95M 10-K · filed 2013-02-15 |
| 2010-09-30 | $1.66M 10-Q · filed 2011-10-27 | $3.74M derived: sum of 2 quarters · filed 2011-10-27 | $5.62M 10-Q · filed 2011-10-27 | $6.83M derived: sum of 4 quarters · filed 2012-02-21 |
| 2010-06-30 | $2.08M 10-Q · filed 2011-07-28 | $3.96M 10-Q · filed 2011-07-28 | $5.17M derived: sum of 3 quarters · filed 2012-02-21 | $6.96M derived: sum of 4 quarters · filed 2012-02-21 |
| 2010-03-31 | $1.89M 10-Q · filed 2011-05-03 | $3.09M derived: sum of 2 quarters · filed 2012-02-21 | $4.88M derived: sum of 3 quarters · filed 2012-02-21 | $6.84M derived: sum of 4 quarters · filed 2012-02-21 |
| 2009-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $3.00M derived: sum of 2 quarters · filed 2012-02-21 | $4.95M derived: sum of 3 quarters · filed 2012-02-21 | $6.43M 10-K · filed 2012-02-21 |
| 2009-09-30 | $1.79M 10-Q · filed 2010-10-28 | $3.75M derived: sum of 2 quarters · filed 2010-10-28 | $5.23M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $1.95M 10-Q · filed 2010-07-28 | $3.44M 10-Q · filed 2010-07-28 | ||
| 2008-12-31 | $7.07M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |